Adverse Drug Reactions to Antiretroviral Therapy (ARVs): Incidence, Type and Risk Factors in Nigeria

Overview

Journal BMC Clin Pharmacol

Publisher Biomed Central

Specialty Pharmacology

Date 2012 Feb 29

PMID 22369677

Citations 41

Authors

George I Eluwa

Titilope Badru

Kenneth A Agu

Kesiena J Akpoigbe

Otto Chabikuli

Christoph Hamelmann

Affiliations

Soon will be listed here.

Abstract

Background: Data on adverse drug reactions (ADRs) related to antiretroviral (ARV) use in public health practice are few indicating the need for ART safety surveillance in clinical care.

Objectives: To evaluate the incidence, type and risk factors associated with adverse drug reactions (ADRs) among patients on antiretroviral drugs (ARV).

Methods: Patients initiated on ARVs between May 2006 and May 2009 were evaluated in a retrospective cohort analysis in three health facilities in Nigeria. Regimens prescribed include nucleoside backbone of zidovudine (AZT)/lamivudine (3TC), stavudine (d4T)/3TC, or tenofovir (TDF)/3TC in combination with either nevirapine (NVP) or efavirenz (EFV). Generalized Estimating Equation (GEE) model was used to identify risk factors associated with occurrence of ADR.

Results: 2650 patients were followed-up for 2456 person-years and reported 114 ADRs (incidence rate = 4.6/100 person-years).There were more females 1706(64%) and 73(64%) of the ADRs were reported by women. Overall, 61(54%) of ADRs were reported by patients on AZT with 54(47%) of these occurring in patients on AZT/NVP. The commonest ADRs reported were pain 25(30%) and skinrash 10(18%). Most ADRs were grade 1(39%) with only 1% being life threatening (grade 4). Adjusted GEE analysis showed that ADR was less likely to occur in patients on longer duration of ART compared to the first six months on treatment; 6-12 months AOR 0.38(95% CI:0.16-0.91) and 12-24 months AOR 0.34(95% CI:0.16-0.73) respectively. Compared to patients on TDF, ADR was less likely to occur in patients on d4T and AZT AOR 0.18(95% CI 0.05-0.64) and AOR 0.24(95% CI:0.7-0.9) respectively. Age, gender and CD4 count were not significantly associated with ADRs.

Conclusion: ADRs are more likely to occur within the first six months on treatment. Close monitoring within this period is required to prevent occurrence of severe ADR and improve ART adherence. Further research on the tolerability of tenofovir in this environment is recommended.

Citing Articles

Time to major adverse drug reactions and its predictors among children on antiretroviral treatment at northwest Amhara selected public hospitals northwest; Ethiopia, 2023.

Tsega B, Habtamu A, Wubie M, Telayneh A, Endalew B, Habtegiorgis S PLoS One. 2024; 19(10):e0309796.

PMID: 39361573 PMC: 11449323. DOI: 10.1371/journal.pone.0309796.

Client-reported challenges and opportunities for improved antiretroviral therapy services uptake at a secondary health facility in Ghana.

Manu E, Sumankuuro J, Douglas M, Aku F, Adoma P, Kye-Duodu G Heliyon. 2024; 10(15):e35788.

PMID: 39170237 PMC: 11337046. DOI: 10.1016/j.heliyon.2024.e35788.

Variation of adverse drug events in different settings in Africa: a systematic review.

Nyame L, Hu Y, Xue H, Fiagbey E, Li X, Tian Y Eur J Med Res. 2024; 29(1):333.

PMID: 38880895 PMC: 11181533. DOI: 10.1186/s40001-024-01934-0.

Pulmonary Cryptococcosis: A Diagnostic and Management Challenge Case Report.

Cardoso K, Carroll L Cureus. 2024; 16(4):e59361.

PMID: 38817470 PMC: 11138369. DOI: 10.7759/cureus.59361.

Factors associated with anti-retroviral therapy (ART) adherence among adult people living with HIV (PLWH): A 5-year retrospective multi-centre study in Kumasi, Ghana.

Senu E, Sakyi S, Ayisi-Boateng N, Enimil A, Opoku S, Ansah R Dialogues Health. 2024; 1:100082.

PMID: 38515921 PMC: 10954008. DOI: 10.1016/j.dialog.2022.100082.

References

Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R . Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002; 35(1):182-9. DOI: 10.1053/jhep.2002.30319. View

Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G . Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005; 353(22):2325-34. DOI: 10.1056/NEJMoa051908. View

Gazzard B, Bernard A, Boffito M, Churchill D, Edwards S, Fisher N . British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006; 7(8):487-503. DOI: 10.1111/j.1468-1293.2006.00424.x. View

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

Lucas G, Chaisson R, Moore R . Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999; 131(2):81-7. DOI: 10.7326/0003-4819-131-2-199907200-00002. View

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A . Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antivir Ther. 2005; 10(5):615-24. DOI: 10.1177/135965350501000510. View

Subbaraman R, Chaguturu S, Mayer K, Flanigan T, Kumarasamy N . Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007; 45(8):1093-101. DOI: 10.1086/521150. View

Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N . Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One. 2011; 6(3):e17609. PMC: 3047584. DOI: 10.1371/journal.pone.0017609. View

Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P . Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000; 23(3):236-45. DOI: 10.1097/00126334-200003010-00004. View

10.

Laurent C, Bourgeois A, Mpoudi-Ngole E, Ciaffi L, Kouanfack C, Mougnutou R . Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses. 2008; 24(3):393-9. DOI: 10.1089/aid.2007.0219. View

11.

Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N . Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007; 44(4):371-6. DOI: 10.1097/QAI.0b013e318032bbee. View

12.

de Maat M, Ter Heine R, van Gorp E, Mulder J, Mairuhu A, Beijnen J . Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS. 2003; 17(15):2209-14. DOI: 10.1097/00002030-200310170-00009. View

13.

Severe P, Juste M, Ambroise A, Eliacin L, Marchand C, Apollon S . Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010; 363(3):257-65. PMC: 3676927. DOI: 10.1056/NEJMoa0910370. View

14.

Idoko J, Akinsete L, Abalaka A, Keshinro L, Dutse L, Onyenekwe B . A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. West Afr J Med. 2002; 21(2):83-6. View

15.

Liang K, Zeger S . Regression analysis for correlated data. Annu Rev Public Health. 1993; 14:43-68. DOI: 10.1146/annurev.pu.14.050193.000355. View

16.

Pollard R, Robinson P, Dransfield K . Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1999; 20(6):1071-92. DOI: 10.1016/s0149-2918(98)80105-7. View

17.

Duval X, Journot V, Leport C, Chene G, Dupon M, Cuzin L . Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis. 2004; 39(2):248-55. DOI: 10.1086/422141. View

18.

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S . Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007; 8(6):357-66. DOI: 10.1111/j.1468-1293.2007.00477.x. View

19.

Baylor M, Johann-Liang R . Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004; 35(5):538-9. DOI: 10.1097/00126334-200404150-00014. View

20.

Montessori V, Press N, Harris M, Akagi L, Montaner J . Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170(2):229-38. PMC: 315530. View